⌕
Climb Bio · CLYM · Nasdaq
Tenet 62 · Solid
Compare
$9.78−1.61%At closeTenet 62 · Solid
$9.78−0.16 (−1.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Climb Bio (CLYM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CLYM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 t…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition

WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that me…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireOct 24, 2026 · 19:30 ETCOMPANY'S OWN WORDS
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireOct 23, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first …

CLYM −1.6% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 10:41 ET
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?

Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.…

CLYM −1.6% todayRead at source ↗
● Seeking AlphaOct 7, 2026 · 13:10 ET
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash, providing operational runway…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 09:30 ETCOMPANY'S OWN WORDS
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation…

CLYM −1.6% todayRead at source ↗
● MarketBeatSep 3, 2026 · 14:02 ET
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.…

CLYM −1.6% todayRead at source ↗
● BenzingaSep 3, 2026 · 13:52 ET
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting to…

CLYM −1.6% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that m…

CLYM −1.6% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just CLYM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.